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Abstract: Urinary tract infections (UTIs) are associated with significant morbidity. We rely on clinical presentation, urinalysis, and 
urine culture to diagnose UTI. To differentiate between lower UTI and pyelonephritis, we depend on the clinical presentation. In the 
extremes of age and in immunocompromised individuals, clinical presentation is often atypical posing a challenge to diagnosis. In the 
elderly, the high prevalence of asymptomatic bacteriuria is another confounder. We conducted a search of publications to find novel 
biomarkers to diagnose UTI and to ascertain its severity. We searched PUBMED, MEDLINE and SCOPUS databases for studies 
pertaining to novel biomarkers and UTI. Two reviewers independently evaluated the methodology of the studies using the STARD 
(Standards for Reporting of Diagnostic Accuracy) criteria. We have identified procalcitonin as a biomarker to differentiate lower UTI 
from pyelonephritis in the pediatric age group. Elevated serum procalcitonin levels can result in early and aggressive treatment at the 
time of presentation. Interleukin 6 has also shown some promise in differentiating between lower UTI and pyelonephritis but needs 
further validation. Lastly, given the paucity of data in certain subgroups like diabetics, kidney transplant recipients, and individuals 
with spinal cord injury, further studies should be conducted in these populations to improve diagnostic criteria that will inform clinical 
management decisions.
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Introduction
Urinary tract infection (UTI) is a common bacterial 
infection in all age groups. The prevalence in infants 
is 6.5% and 3.3% in girls and boys, respectively.1 
Among infants, approximately 60% of febrile UTIs 
will result in renal scarring which increases the risk 
of secondary hypertension.2,3 In adults age 65 years or 
older, it is the second most common cause of infectious 
disease  related  hospitalizations.4  UTI  accounts  for 
up to 30% of all infectious complications in kidney 
transplant recipients. UTI appearing in the first three 
months of kidney transplantation is associated with 
pyelonephritis, bacteremia, and allograft dysfunction.5 
In individuals with spinal cord injuries (SCI), UTI is 
the second most common cause of death.6 Catheter 
associated  UTI  is  the  most  common  nosocomial 
infection in US hospitals and nursing homes.7 Other 
populations predisposed to UTI include diabetics and 
individuals with polycystic kidney disease. Despite 
significant morbidity associated with UTI, making a 
diagnosis and establishing the severity of infection in 
the urinary tract remains a challenge.
Establishing the severity and extent of infection (i.e. 
lower UTI vs. pyelonephritis) is important to determine 
further  management.  The  duration  of  treatment  in 
uncomplicated UTI (i.e. involving lower urinary tract) 
is  generally  shorter  compared  to  complicated  UTI 
(i.e. involving renal parenchyma).8 If there is renal 
parenchymal  involvement,  the  antibiotic  of  choice 
would be one that has excellent penetration in the 
renal parenchyma. Untreated pyelonephritis in young 
children can lead to secondary hypertension because 
of renal scarring.3 Acute pyelonephritis at the extremes 
of age and in immunocompromised individuals can 
result  in  sepsis,  renal  abscess,  hydronephrosis  and 
rarely  xanthogranulomatous  pyelonephritis.9  The 
typical clinical presentation of lower UTI includes 
frequency, urgency, and dysuria. Classic symptoms 
of pyelonephritis include fever, flank pain along with 
lower  UTI  symptoms.  Often  the  absence  of  fever 
indicates lower UTI and not upper UTI.10 Multiple 
studies have shown that clinical characteristics alone 
are inadequate to localize the site of infection in the 
urinary tract.11–13 Biggi et al showed that high fever was 
not a reliable sign to discriminate pyelonephritis from 
lower UTI. Maximum temperature in the lower UTI 
group and pyelonephritis group was 39 ± 0.7 °C and 
39.2 ± 0.6 °C, respectively (P = 0.91). The sensitivity 
and  specificity  of  temperature  more  than  39.1  °C, 
to  diagnose  pyelonephritis,  was  64%  and  38% 
respectively.11 In another study by Farnsworth et al 
of  the  29  individuals,  12  (41%)  had  parenchymal 
involvement but were afebrile.12
With  the  aforementioned  limitations  of  clinical 
evaluation,  biological  markers  (biomarkers)  may 
have  the  potential  to  diagnose  UTI  and  determine 
the  severity  of  infection.  A  biomarker  is  defined 
as  “a  characteristic  that  is  objectively  measured 
and  evaluated  as  an  indicator  of  normal  biological 
processes,  pathogenic  processes,  or  pharmacologic 
responses to a therapeutic intervention.”14 To differentiate 
between  lower  UTI  and  pyelonephritis,  biomarkers 
like erythocyte sedimentation rate (ESR), C-reactive 
protein (CRP) and white blood count (WBC) have 
been studied in children. The sensitivity of ESR to 
determine  renal  parenchymal  damage  varies  with 
the  cut  off. A  retrospective  study,  using  a  cut  off 
of  10 mm/h  for  ESR  yielded  a  sensitivity  and 
specificity of 100% and 8%.13 A prospective study using 
a cut off  68 mm/hr for ESR yielded a sensitivity and 
specificity of 48% and 50% respectively. For CRP, to 
diagnose pyelonephritis, the sensitivity was 64% and 
specificity was 68%. White blood count of more than 
14,601 cells/mm3 has a sensitivity and specificity of 
56% and 58% to diagnose pyelonephritis.11 Given the 
variable results of  these biomarkers, it is challenging to 
use these biomarkers alone to detect renal parenchymal 
damage and therefore we rely on radiological studies. 
Further, to make a diagnosis of lower UTI, we use 
urinalysis and urine culture results. Given the high 
incidence  of  asymptomatic  bacteriuria  (ASB)  and 
no evidence to treat ASB in the general population, 
differentiating between UTI and ASB is imperative. 
Leukocyte esterase and nitrite are biomarkers measured 
in urinalysis for diagnosing UTI. The absence of either 
of these biomarkers makes either condition extremely 
unlikely.15 However, the presence of either or both 
of these biomarkers does not assist in differentiating 
ASB from UTI. Therefore, novel biomarkers that can 
assist in the diagnosis and determination of severity of 
disease for UTI need to be identified.
Methods
Studies eligible for review
Studies  evaluating  serum  and  urine  biomarkers 
for the diagnosis of UTI in humans were included. Biomarkers for urinary tract infection
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Prospective, retrospective, cohort, case control studies, 
or randomized controlled trials were included.
Finding relevant studies
PUBMED, MEDLINE and SCOPUS databases were 
searched  for  “urinary  tract  infection”,  “biological 
marker” and “diagnosis” and then limited to studies 
published in the English language from 1997 through 
2008 in human subjects. After selecting and reviewing 
relevant  articles,  we  identified  potential  novel 
biomarkers.  We  identified  novel  biomarkers  based 
on the number and quality of studies conducted for 
a given biomarker. Then we searched all databases 
(PUBMED, MEDLINE and SCOPUS) using “urinary 
tract infection” with each potential novel biomarker, 
with the same limits noted above.
Quality assessment
The STARD (Standards for Reporting of Diagnostic 
Accuracy) criteria were utilized to assess the validity 
of the studies.16 The studies were graded based on a 
checklist that included nine STARD criteria relevant 
to this review (see Table 1). Studies were divided 
into three categories based on scores. A score of 8–9 
indicates good quality, 6–7 indicates fair quality, and 
5 or less is categorized as poor quality. Two reviewers 
independently  graded  the  studies.  Disagreements 
were discussed until a consensus was reached.
Results
Six hundred seventy three citations were identified 
with  the  initial  search,  of  which  21  articles  were 
selected.  Articles  that  were  excluded  were  not 
relevant to our study question, i.e. did not discuss UTI 
and  novel  biomarkers.  We  identified  procalcitonin 
(PCT), interleukin 6 (IL-6) and interleukin 8 (IL-8) 
as potential novel biomarkers for diagnosing urinary 
tract infection and assessing the severity of infection. 
With the second search (“urinary tract infection” with 
“PCT” or “IL-6”or “IL-8”), six additional articles were 
retrieved. A full text analysis of 27 articles resulted in 
the inclusion of 26 studies (see Fig. 1). Two studies 
were deemed of good quality and fourteen studies 
were of fair quality. The remaining studies were of 
Table 1. Scoring system for validity based on the STARD criteria.
Validity criterion Description scoring
Participant recruitment was recruitment based on presenting 
symptoms or not?
Presenting symptoms (1)  
No presenting symptoms (0)
Participant sampling was the study population a convenience sample 
or consecutive series of participants defined by 
the inclusion and exclusion criteria, setting and 
locations where data were collected?
Consecutive series (1) 
Convenience sample (0)
Data collection was data collection planned before the 
index test and reference standard test 
(i.e. prospectively or retrospectively)?
Prospectively (1) 
Retrospectively (0)
Reference standard was the rationale for reference standard 
stated?
Stated (1) 
Not stated (0)
Materials and methods Were technical specifications of materials 
and methods including how and when 
measurements were taken stated?
Stated (1) 
Not stated (0)
Index test Were the definition of and rationale for the units, 
cut offs of the results of the index tests and 
reference standards stated?
Stated (1) 
Not stated (0)
Blinding Readers of index test and reference standard 
blinded?
Blinded (1) 
Not blinded or not stated (0)
Completion was the number of participants that did not 
undergo index tests (#test vs. sample size) 
stated?
Stated (1) 
Not stated (0)
Time Interval  was the time interval from index test to  
reference standard stated?
Stated (1) 
Not stated (0)Nanda and Juthani-Mehta
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poor quality. One study was not scored because of 
inadequate information (see Tables 2 and 3).
All studies deemed as good and fair quality are 
discussed in this review.
Procalcitonin (PCT)
Procalcitonin  (PCT)  is  a  propeptide  of  calcitonin. 
It was first described by Assicot et al as a marker of 
bacterial invasion.17 In healthy humans, it is produced 
in the C-cells of the thyroid gland, and during a severe 
bacterial infection, it is produced by the monocyte-
macrophage system. In humans, after the 3rd day of 
life, a normal plasma PCT level is less than 0.5 µg/l.
Eight  articles  studying  serum  PCT  and  urinary 
tract  infection  were  identified.  One  study  was  of 
good quality, five were fair and the remaining were of 
poor quality.18 Most of these studies were conducted 
in the pediatric age group with an aim to differentiate 
673 citations identified 
21 articles 
652 excluded because not a 
study of UTI and biomarkers 
Search with “UTI”, 
“biological marker” and 
“diagnosis” 
27 articles 
Search conducted with potential 
novel biomarker and UTI 
resulted in identification of 6 
additional citations 
26 articles included  
1 article excluded after detailed 
review because it was an 
editorial comment 
PCT 
(n = 8) 
ILs
(n = 11)
a
Misc
(n = 8) 
Serum 
(n = 8)
Serum
(n = 2)
b
Urine 
(n = 10)
Serum 
(n = 5)
c
Urine 
(n = 7)
Figure 1. Selection of studies.
aOne study discussing PCT and IL; bOne study discussing IL in both serum and urine; cFour studies discussing biomarkers in both serum and urine.
Abbreviations: UTI, urinary tract infection PCT, procalcitonin ILs, interleukins. Biomarkers for urinary tract infection
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between  acute  pyelonephritis  and  lower  UTI.  The 
reference standard for parenchymal damage in all of 
these  studies  was  99mTc-dimercaptosuccinic  acid 
(DMSA) scintigraphy.
Benador et al conducted a prospective study in 
80 children who were 1 month to 16 years of age. 
At  presentation,  PCT,  C  reactive  protein  (CRP) 
and white blood cell count (WBC) were compared 
in  children  with  pyelonephritis  and  lower  UTI.18 
There  were  statistically  significant  differences 
between the two groups for all three parameters, but 
only  PCT  had  a  good  correlation  with  increasing 
severity of scintigraphic changes noted on DMSA. 
In  the  pyelonephritis  group,  PCT  was  5.37 µg/L 
(95%  confidence  interval  [CI]  1.57  to  9.17)  and 
0.38 µg/L  (95%  CI  0  to  0.76)  in  the  lower  UTI 
Table 2. Score based on STARD criteria.
Reference Biomarker serum/urine score
Procalcitonin (PCT)
Pecile et al22 PCT Serum 8
Guven et al23 PCT Serum 7
Benador et al18 PCT Serum 7
*Gurgoze et al19 PCT, IL-1β, IL-6 and TNF-α Serum 7
Grevaix et al20 PCT Serum 6
Smolkin et al21 PCT Serum 6
Prat et al39 PCT Serum 5
Tuerlinckx et al40 PCT Serum 4
Interleukins (ILs)
Sheu et al26 IL-6 and IL8 Serum and Urine 7
Olszyna et al24 IL-8 Urine 7
Sheu et al29 IL-1β Urine 6
Krzemein et al27 IL-6 and IL-8 Urine 6
Otto et al28 Chemokines Serum and Urine 6
Jantausch et al25 IL-6 and IL-8 Urine 6
Roilides et al41 IL-6 Urine 5
Zaki et al42 IL-8 Urine 5
Oregioni et al43 IL-8 Urine 3
Rao et al44 IL-8 Urine 3
Miscellenous
Fretzayas et al30 e-a1-Pi Urine and plasma 8
Arao et al31 Lactoferrin Urine 6
Deo at al32 Secretory IgA Urine 6
Bakokas et al33 e-a1-Pi Urine and plasma 5
Smith et al35 NBT reduction Urine 5
everaert et al34 α-1 microglobulin/serum  
prostatic antigen
Urine-α-1 microglobulin and Serum 
prostatic antigen
4
Steinhoff et al36 Myeloperoxidase, CRP and  
α2-macroglobulin
Urine-myeloperoxidase and  
α-2 macroglobulin; serum CRP
3
Determann et al45  Soluble triggering receptor  
expressed on myeloid cells-1
Serum  NA 
*Study evaluating PCT, IL-1β, IL-6 and TNF-α.Nanda and Juthani-Mehta
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group. Gürgoze et al conducted a prospective study 
in 76 children with UTI.19 There were 34 subjects in 
the acute pyelonephritis group and 42 in lower UTI 
group.  Median  PCT  level  obtained  at  presentation 
was significantly higher in the acute pyelonephritis 
group, i.e. 1.68 ng/ml (range 0.14 to 5.4) vs. 0.1 ng/ml 
(range 0.1 to 3.2), P  0.001. Using a cut-off of  0.5 ng/ml, 
to  diagnose  pyelonephritis,  the  sensitivity  and 
specificity of PCT was 94% and 58% respectively.
In a smaller group of children (n = 54), Grevaix 
et al also confirmed a higher level of PCT in the setting 
of parenchymal damage compared with lower UTI.20 
In another prospective study of 64 children, Smolkin 
et al demonstrated that in acute pyelonephritis, the 
median  PCT  was  3.41 µg/L  (range  0.36  to  12.4) 
while in lower UTI, the median PCT was 0.13 µg/L 
(range 0.02 to 2.15), P  0.0001.21 In this study, using 
a cut-off of 0.5 µg/L, PCT had a sensitivity of 94.1% 
and specificity of 89.7% for detecting pyelonephritis.
Pecile et al prospectively showed that PCT can 
serve as a marker of severity of acute pyelonephritis 
in children.22 The study included 100 children. Mean 
PCT increased proportionally with the extent of renal 
involvement (P  0.0001). PCT levels at admission 
were  lower  in  patients  with  completely  reversible 
lesions (mean 3.25 ng/ml, 95% CI 0 to 10.25) versus 
those with partially reversible lesions or renal scarring 
(mean 7.48 ng/ml, 95% CI 0 to 24.28), P = 0.04. A cut-
off  value  of  0.8 ng/ml  yielded  the  best  diagnostic 
accuracy with a sensitivity of 83.3% and specificity 
of 93.7% to diagnose acute pyelonephritis.
Lastly, Guven et al conducted a prospective study 
with 33 children and were unable to show a significant 
correlation between parenchymal damage and PCT, CRP 
and WBC. 23 Subjects were enrolled based on presenting 
symptoms and diagnosis of acute pyelonephritis was 
confirmed with DMSA. In summary, PCT is a good 
marker to predict renal parenchymal damage in the 
pediatric age group. It has not been studied in other 
populations to make a diagnosis of UTI or to identify 
renal parenchymal damage as a result of infection.
Interleukins (ILs)
Interleukins  are  a  family  of  cytokines  that  play  a 
key  role  in  the  regulation  of  the  immune  system. 
We identified 11 articles studying interleukins in the 
setting  of  UTI.  Seven  articles  were  graded  as  fair 
quality and the rest were poor quality. Interleukin 6 
(IL-6) and interleukin 8 (IL-8) have been studied in 
adults to diagnose UTI and in children to differentiate 
between pyelonephritis and lower UTI.
Urinary IL-8 has been suggested as a biomarker for 
UTI in catheterized postoperative patients. In a study 
by Olsyzna et al, urinary IL-8 and IL-6 were measured 
prospectively.24 A diagnosis of UTI was made if the 
patient had at least one clinical symptom of UTI plus 
greater than 100,000 CFU/ml on urine culture. One 
hundred and sixty five patients were initially enrolled 
and 10 were diagnosed with UTI. Twenty patients, 
matched  for  duration  of  catheterization,  served  as 
controls. Urinary IL-8 increased on the day the urine 
culture became positive in the UTI group, while in the 
control group it was unchanged. Urinary IL-8 increased 
from approximately 10 to 125 ng/mmol of creatinine in 
the UTI group and remained constant at approximately 
10 ng/mmol of creatinine in the control group. Urinary 
IL-6 increased in both the case and control groups.
Jantausch  et  al  prospectively  studied  urinary 
IL-6 and IL-8 as markers for UTI in children age 0–12 
years.25 Bacterial UTI was defined as a urine culture 
with  greater  than  100,000  CFU/ml  in  a  midstream 
clean catch specimen or greater than 10,000 CFU/ml 
in a catheterized specimen. The control group included 
febrile  subjects  with  infections  other  than  UTI. 
At the time of admission, the median urinary IL-6 
concentration for subjects (n = 37) with proven bacterial 
UTI was 397 pg/ml (range 0 to 65,790 pg/ml) vs. 
0 pg/ml (range 0 to 473.8 pg/ml) for controls (n = 37), 
P  0.0001. The median urinary IL-8 concentration 
for the bacterial UTI group (n = 32) was 5809 pg/ml 
(range 0 to 347,368 pg/ml) vs. 0 (range 0 to 2231 pg/ml) 
for the controls (n = 32), P  0.0001.
Sheu  et  al  compared  the  utility  of  serum  and 
urine  levels  of  IL-6  and  IL-8  for  diagnosing  acute 
pyelonephritis.26 Seventy eight children aged 1–121 
months with a first episode of febrile UTI were included. 
Twelve healthy children who were matched for age and 
sex served as controls. All patients with suspected UTI 
received antibiotics at the time of presentation. Serum 
and urine IL-6 and IL-8 were collected at presentation. 
Acute pyelonephritis was confirmed with DMSA. The 
initial value of both interleukins in serum and urine was 
significantly higher in patients with acute pyelonephritis 
(n = 42) compared with lower UTI (n = 36) and healthy 
controls (n = 12). Serum IL-6 was 67.5 ± 75.4 pg/ml 
(mean ± standard deviation [SD]) in the pyelonephritis Nanda and Juthani-Mehta
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group, 12.1 ± 15.0 pg/ml in the lower UTI group and 1.6 
to 2.8 pg/ml in the healthy controls, P  0.001. Urine 
IL-6 was 516 ± 685.9 pg/mg of creatinine (mean ± SD) 
in  the  pyelonephritis  group,  46.9 ± 78.8  pg/mg  in 
lower  UTI  group  and  was  undetectable  in  healthy 
control  group,  P  0.001.  IL-6  in  serum  and  urine 
significantly correlated with each other and with fever, 
CRP and leukocytes in the urine. Serum IL-8 was 29.2 ± 
27.3 pg/ml (mean ± SD) in the pyelonephritis group, 
7 ± 9.2 pg/ml in lower UTI group and 1.5 ± 3.6 pg/ml 
in  the  healthy  controls,  P  0.001.  Urine  IL-8  was 
3165.8 ± 4665.1 pg/mg of creatinine (mean ± SD) in 
the  pyelonephritis  group,  172 ± 350.8 pg/mg  in  the 
lower UTI group and 11.2 ± 15.1 pg/mg in the healthy 
control group, P  0.001. Serum IL-8 and urinary IL-8 
significantly correlated with each other but not with 
clinical symptoms. Of note, the standard deviation was 
larger than the mean value in most cases. Serum and 
urine IL-6 had a higher sensitivity and specificity to 
diagnose acute pyelonephritis compared to serum and 
urine IL-8.29 Sensitivity and specificity for serum IL-6, 
using a cut-off value of 22 pg/ml was 88% and 83%, 
respectively. For urine IL-6, using a cut-off value of 
70 pg/mg of creatinine, sensitivity and specificity was 
86% and 81% respectively.
Gürgoze et al showed that at the time of  presentation, 
median serum IL-6 was higher in the pyelonephritis 
group compared with the lower UTI group, 59 pg/ml 
(range 0–357.2) vs. 10 pg/ml (range 0–64), P  0.001.19 
This study was conducted in children less than one 
year of age. To diagnose pyelonephritis, using a cut-
off of 18 pg/ml for serum IL-6, yielded a sensitivity 
of 88% and a specificity of 74%.
Contrary to Sheu et al, Krzemień et al showed no 
difference in urinary IL-6 and IL-8 in subjects with 
acute pyelonephritis and UTI. Krzemień et al studied 
33 children in the age group of 1–24 months who were 
admitted with the first episode of UTI. Urinary IL-6 
measured as urinary IL-6/creatinine was not significantly 
different  in  the  pyelonephritis  and  UTI  groups 
(median 2.83 pg/mg, range 0 to 122.55 vs. 3.81 pg/mg, 
range 0 to 41.67).27 Median urinary IL-8 measured 
as  urinary  IL-8/creatinine  was  45.12  pg/mg  (range 
0 to 3200.77) in the pyelonephritis group and 0 pg/ml 
(range 0 to 117.45) in the UTI group. The difference 
between the two groups was not significant.
Otto et al prospectively studied the serum chemokine 
profile of adults (age 18–85 year old) with febrile UTI.28 
Serum IL-8 concentration was higher in patients with 
clinical signs of acute pyelonephritis than in the group 
with lower UTI symptoms. In the pyelonephritis group, 
median IL-8 was 1.45 ng/ml (range 0.31 to 7.70) and 
0.88 ng/ml  (range  0.20  to  4.10)  in  the  lower  UTI 
group but the difference was not significant.
IL-1 is another immunoregulatory cytokine. IL-1β 
is a subtype of  IL-1, found in free form in biological fluids 
like serum, urine, and synovial fluid. IL-1β has also been 
studied to differentiate between acute pyelonephritis 
and lower UTI. In addition to investigating PCT and 
IL-6,  Gurgoze  et  al  determined  that  serum  IL-1β 
had a sensitivity of 97% and a specificity of 59% for 
detecting pyelonephritis.19 A cut-off of 6.9 pg/ml was 
used to distinguish between pyelonephritis and lower 
UTI. In the pyelonephritis group, median IL-1β was 
32.3 pg/ml (range 1.63 to 70.2) and in the lower UTI 
group, median IL-1β was 1.64 pg/ml (range 0 to 14.55), 
P  0.001. Similarly, urinary IL-1β proved to be a 
helpful marker in another study comparing patients with 
acute pyelonephritis (n = 41), lower UTI (n = 34), and 
febrile controls (n = 20, patients with upper respiratory 
infection, lower respiratory infection, otitis media, and 
gastroenteritis).29 There was a significant difference in 
IL-1β levels at presentation in all three groups; acute 
pyelonephritis  (172 ± 263.3  pg/ml,  mean ± SD), 
lower UTI (20.4 ± 41.2 pg/ml) and febrile controls 
(4.6 ± 14 pg/ml).
IL-6 and IL-8 have been studied in several settings 
including  diagnosing  UTI  in  adults  in  the  post-
operative  setting,  in  diagnosing  bacterial  UTI  in 
children, and in diagnosing pyelonephritis in children. 
Serum IL-6 is a possible novel biomarker to diagnose 
acute pyelonephritis in children but further studies 
are warranted. Currently, there are discrepant results 
when using urinary IL-6, serum and urinary IL-8 to 
diagnose acute pyelonephritis in children and adults.
Miscellaneous
Besides PCT and IL, other novel biomarkers have 
been  studied  to  diagnose  UTI. We  identified eight 
articles discussing these biomarkers. Among these, 
the article regarding polymorphonuclear elastase was 
rated  as  a  good  quality  article.  Studies  discussing 
urinary  lactoferrin  and  urinary  secretory  IgA  were 
fair quality based on our scores.
Elastase is a protease stored in neutrophils. It is 
present  in  plasma  and  urine  in  a  formed  complex Biomarkers for urinary tract infection
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(elastase-a1-antitrypsin  complex,  E-a1-Pi).  Fretzayas 
et al investigated the utility of E-a1-Pi for detecting 
pyelonephritis in children with UTI.30 Eighty three 
children below the age of 14 were enrolled. The first 
episode of symptomatic UTI with a single organism 
(105  CFU/ml)  with  or  without  fever  was  the 
inclusion  criteria.  DMSA  was  used  to  confirm  the 
diagnosis of pyelonephritis. Plasma E-a1-Pi levels were 
significantly elevated in patients with pyelonephritis 
(n = 30) compared with patients without parenchymal 
involvement (n = 53), 103.5 ± 9.3 µg/ml vs. 54.1 ± 
6.5 µg/ml  (mean ± standard  error)  respectively, 
P  0.01.  Urinary  E-a1-Pi  showed  no  significant 
difference between the two groups.
Polymorphonuclear  leukocytes  (PMNs)  contain 
lactoferrin  (LF),  a  stable  iron  binding  protein. 
Arao et al studied its usefulness for screening UTI, 
defined as the presence of a clinical symptom along 
with 10/mm3 PMN and 1000 CFU/ml bacteria 
in a urine sample.31 Patients with lower UTI, acute 
pyelonephritis,  and  complicated  UTI  (defined  as 
having underlying urinary tract disease) were included, 
and urinary LF was measured in patients with UTI 
and without UTI using an immunochromatographic 
assay. Subjects with UTI (n = 60) had a high mean 
urinary lactoferrin at 3.3 µg/ml (95% CI, 2.02–4.58) of 
urine while in the group without UTI (n = 121) it was 
0.030 µg/ml (95% CI, 0.025–0.035) of urine. A cutoff 
value of 200 ng/ml yielded a sensitivity of 93.3% and 
specificity of 89.3% for PMNs in the urine.
Secretory  immunoglobulin  A  is  produced  by 
plasma cells in mucous membranes. It is also found 
in the urine of healthy individuals. Deo et al showed 
in  subjects  with  UTI,  there  was  more  than  a  two 
standard deviation increase compared with uninfected 
subjects.32 This marker was also increased in subjects 
with glomerular and anatomical pathology. These data 
suggest that sIgA may be used as a screening test or in 
conjunction with other markers for diagnosing UTI.
Other biomarkers such as soluble triggering receptor 
expressed on myeloid cells-1, urinary myeloperoxidase, 
α-2  macroglobulin,  and  the  ratio  of  urinary  α-1 
microglobulin and serum prostatic antigen have also been 
studied to diagnose UTI, differentiate between upper 
and lower UTI and UTI from renal graft rejection.33–36
Since most of studies done in this group were of 
poor quality, it is challenging to advocate the use of 
these markers in clinical practice.
Discussion
We have conducted an extensive literature review for 
novel biomarkers that would help in the diagnosis of 
UTI and assist in establishing its severity. We have 
identified procalcitonin (PCT) as a potential biomarker 
that can help in differentiating between lower UTI 
and pyelonephritis in the pediatric age group.
Lower UTI vs. pyelonephritis
Procalcitonin  (PCT),  interleukin  6  (IL-6),  and 
interleukin 8 (IL-8) have been studied to diagnose 
acute pyelonephritis at an early stage. PCT has shown 
promising results in this setting. The sensitivity and 
specificity of PCT ranges from 58% to 94.1% and 
36.4% to 93.6%, respectively. These numbers are based 
on the studies graded as good and fair quality in this 
review. Most of these studies enrolled children who 
were less than 1 year to 12 years of age. PCT has not 
been studied in other populations in the setting of UTI. 
Serum IL-6 has shown some promise in differentiating 
between acute pyelonephritis and lower UTI in two 
studies.19,26 Both these studies were done in children 
less  than  12  years  of  age.  Interleukin  8  has  been 
studied with negative results in a similar setting.
Approximately 60% of children with febrile UTI 
develop acute pyelonephritis and 30% of those develop 
renal scars. 99mTc-dimercaptosuccinic acid (DMSA) 
scintigraphy  is  the  gold  standard  used  to  diagnose 
renal scars. This is often performed six months after 
the acute presentation. DMSA is not available in all 
settings and involves radiation exposure. PCT is a 
potential biomarker that can be used in settings where 
DMSA may not be readily available. This can predict 
renal parenchymal damage at the time of presentation 
in the pediatric age group. A recent prospective study 
comparing PCT, ESR and CRP showed superior results 
with  PCT  to  assess  renal  parenchymal  damage.37 
Furthermore, a high PCT (0.5 ng/ml) has shown to 
be associated with vesicoureteral reflux in children.38 
It  is  a  non-invasive  test  that  can  help  physicians 
make  decisions  regarding  management  and  further 
assessment.1 Given the wide ranges in sensitivity and 
specificity, further study of PCT to distinguish lower 
UTI from pyelonephritis is warranted.
Diagnosis of lower UTI
We identified three studies using urine interleukin 8   
(IL-8) and lactoferrin (LF) to diagnose UTI. All three Nanda and Juthani-Mehta
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studies were fair quality. Urinary IL-8 has been studied 
in individuals above 18 years of age to diagnose UTI 
in the post operative setting. This biomarker was also 
found to be significantly higher in children, less than 
12 years of age, with febrile UTI compared with children 
with fevers because of another cause. Urinary LF has 
also been studied with positive results to diagnose UTI 
in adults. To date, leukocyte esterase and nitrite are the 
two urinary biomarkers investigated most thoroughly. 
When  leukocyte  esterase  (LE)  and  nitrite  are  use 
together,  the  sensitivity  is  100%  (95%  confidence 
interval  [CI],  91%–100%),  the  specificity  is  20% 
(95% CI, 11%–32%), the positive predictive value is 
45% (95% CI, 34%–56%), and the negative predictive 
value  is  100%  (95%  CI,  74%–100%).15  Therefore, 
presence  of  either  or  both  LE  and  nitrite  does  not 
confirm the diagnosis of UTI. Since the number of 
studies addressing this problem are few, one cannot 
advocate the use of urinary IL-8 and LF biomarkers in 
clinical practice. At this time, however further studies 
combining the use of LE and nitrite with urinary LF 
and IL-8 are likely to be helpful.
Special populations
We  were  unable  to  identify  studies  targeted  to 
populations like individuals with spinal cord injury, 
diabetics, individuals with polycystic kidney disease, 
and the elderly (adults 65 years or older). One study 
specially  focusing  on  kidney  transplant  recipients 
was identified.36 This study aimed at differentiating 
between UTI and allograft rejection based on a panel 
of  biomarkers.  At  this  time,  no  recommendations 
can be made for diagnosing UTI or ascertaining the 
severity of infection in these populations.
Proposed research agenda
To further our ability to diagnose the manifestations of 
bacterial infections in the urinary tract, the following 
areas may serve as topics for future research.
•  PCT is a promising biomarker in the pediatric age 
group  for  diagnosing  acute  pyelonephritis.  This 
should be studied in other populations as well.
•	 Serum IL-6 needs to be studied in a larger population to 
establish its potential as a biomarker to diagnose UTI.
•	 Target  studies  to  other  subgroups  including 
individuals  with  spinal  cord  injury,  diabetics, 
individuals  with  polycystic  kidney  disease,  and 
the elderly (adults 65 years or older) such that they 
may have direct applicability to patient care.
•	 Continued search for additional novel biomarkers, 
that  are  specific  to  the  urinary  system,  to 
diagnose UTI.
As studies in this field progress, it is conceivable 
that one may be able to develop a weighted model 
that uses the information on the available biomarkers. 
With this information one can compute a cumulative 
score  to  differentiate  between  ASB  and  UTI  and 
identify renal parenchymal damage earlier on.
Acknowledgements
We would like to thank Dr. Chirag Parikh for his 
guidance  with  this  manuscript.  Dr.  Juthani-Mehta 
is supported by NIH/NIA Claude D. Pepper Older 
Americans  Independence  Center  (P30-AG21342); 
NIA R03-AG028057; NIA K23-AG028691; Atlantic 
Philanthropies;  IDSA/NFID;  John  A.  Hartford 
Foundation;  Association  of  Specialty  Professors; 
CTSA  Grant  Number  UL1  RR024139  from  the 
National Center for Research Resources (NCRR).
Disclosures
The authors report no conflicts of interest.
References
  1.  Bressan S, Andreola B, Zucchetta P, et al. Procalcitonin as a predictor of 
renal scarring in infants and young children. Pediatric nephrology. 2009; 
24(6):1199–204.
  2.  Hoberman A, Charron M, Hickey RW, Baskin M, Kearney DH, Wald ER. 
Imaging studies after a first febrile urinary tract infection in young children. 
The New England Journal of Medicine. 2003;348(3):195–202.
  3.  Jacobson  SH,  Eklof  O,  Eriksson  CG,  Lins  LE,  Tidgren  B,  Winberg  J. 
Development of hypertension and uraemia after pyelonephritis in childhood: 
27 year follow up. BMJ (Clinical research ed.). 1989;299(6701):703–6.
  4.  Curns AT, Holman RC, Sejvar JJ, Owings MF, Schonberger LB. Infectious 
disease hospitalizations among older adults in the United States from 1990 
through 2002. Archives of Internal Medicine. 2005;165(21):2514–20.
  5.  Charfeddine K, Zaghden S, Kharrat M, Kamoun K, Jarraya F, Hachicha J. 
Infectious  complications  in  kidney  transplant  recipients:  a  single-center 
experience. Transplantation proceedings. 2005;37(6):2823–5.
  6.  Frankel HL, Coll JR, Charlifue SW, et al. Long-term survival in spinal cord 
injury: a fifty year investigation. Spinal Cord. 1998;36(4):266–74.
  7.  Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely 
symptomatic: a prospective study of 1,497 catheterized patients. Archives of 
Internal Medicine. 2000;160(5):678–82.
  8.  Lichtenberger P, Hooton TM. Complicated urinary tract infections. Current 
Infectious Disease Reports. 2008;10(6):499–504.
  9.  Tenner SM, Yadven MW, Kimmel PL. Acute pyelonephritis. Preventing 
complications through prompt diagnosis and proper therapy. Postgraduate 
Medicine. 1992;91(2):261–8.
10.  Sobel JD and Kaye D. Urinary tract infections. In: GL Mandell JB, Raphael 
Dolin, ed Principles and Practice of Infectious Diseases. 2005:875–901.
11.  Biggi A, Dardanelli L, Pomero G, et al. Acute renal cortical scintigraphy 
in children with a first urinary tract infection. Pediatric nephrology (Berlin, 
Germany). 2001;16(9):733–8.Biomarkers for urinary tract infection
Biomarker Insights 2009:4  121
publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
12.  Farnsworth  RH,  Rossleigh  MA,  Leighton  DM,  Bass  SJ, 
Rosenberg  AR.  The  detection  of  reflux  nephropathy  in  infants  by 
99mtechnetium dimercaptosuccinic acid studies. The Journal of Urology. 1991; 
145(3):542–6.
13.  Garin EH, Olavarria F, Araya C, Broussain M, Barrera C, Young L. Diagnostic 
significance of clinical and laboratory findings to localize site of urinary 
infection. Pediatric Nephrology (Berlin, Germany). 2007;22(7):1002–6.
14.  Biomarkers and surrogate endpoints: preferred definitions and conceptual 
framework. Clinical Pharmacology and Therapeutics. 2001;69(3):89–95.
15.  Juthani-Mehta M, Tinetti M, Perrelli E, Towle V, Quagliarello V. Role of 
dipstick testing in the evaluation of urinary tract infection in nursing home 
residents. Infect Control Hosp Epidemiol. 2007;28(7):889–91.
16.  Bossuyt  PM,  Reitsma  JB,  Bruns  DE,  et  al.  The  STARD  statement  for 
reporting  studies  of  diagnostic  accuracy:  explanation  and  elaboration. 
Annals of Internal Medicine. 2003;138(1):W1–12.
17.  Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High 
serum procalcitonin concentrations in patients with sepsis and infection. 
Lancet. 1993;341(8844):515–8.
18.  Benador N, Siegrist CA, Gendrel D, et al. Procalcitonin is a marker of 
severity of renal lesions in pyelonephritis. Pediatrics. 1998;102(6):1422–5.
19.  Gurgoze MK, Akarsu S, Yilmaz E, et al. Proinflammatory cytokines and 
procalcitonin in children with acute pyelonephritis. Pediatric Nephrology 
(Berlin, Germany). 2005;20(10):1445–8.
20.  Gervaix A, Galetto-Lacour A, Gueron T, et al. Usefulness of procalcitonin 
and C-reactive protein rapid tests for the management of children with 
urinary tract infection. The Pediatric Infectious Disease Journal. 2001;20(5): 
507–11.
21.  Smolkin V, Koren A, Raz R, Colodner R, Sakran W, Halevy R. Procalcitonin 
as  a  marker  of  acute  pyelonephritis  in  infants  and  children.  Pediatric 
Nephrology (Berlin, Germany). 2002;17(6):409–12.
22.  Pecile P, Miorin E, Romanello C, et al. Procalcitonin: a marker of severity 
of acute pyelonephritis among children. Pediatrics. 2004;114(2):e249–54.
23.  Guven AG,  Kazdal  HZ,  Koyun  M,  et  al. Accurate  diagnosis  of  acute 
pyelonephritis:  How  helpful  is  procalcitonin?  Nuclear  Medicine 
Communications. 2006;27(9):715–21.
24.  Olszyna  DP,  Vermeulen  H,  Baan  AH,  et  al.  Urine  interleukin-8  is  a 
marker  for  urinary  tract  infection  in  postoperative  patients.  Infection. 
2001;29(5):274–7.
25.  Jantausch BA, O’Donnell R, Wiedermann BL. Urinary interleukin-6 and 
interleukin-8 in children with urinary tract infection. Pediatric Nephrology 
(Berlin, Germany). 2000;15(3–4):236–40.
26.  Sheu JN, Chen MC, Lue KH, et al. Serum and urine levels of interleukin-6 
and interleukin-8 in children with acute pyelonephritis. Cytokine. 2006; 
36(5–6):276–82.
27.  Krzemien  G,  Roszkowska-Blaim  M,  Kostro  I,  et  al.  Urinary  levels  of 
interleukin-6 and interleukin-8 in children with urinary tract infections to 
age 2. Med Sci Monit. 2004;10(11):CR593–7.
28.  Otto G, Burdick M, Strieter R, Godaly G. Chemokine response to febrile 
urinary tract infection. Kidney International. 2005;68(1):62–70.
29.  Sheu JN, Chen MC, Cheng SL, Lee IC, Chen SM, Tsay GJ. Urine interleukin-1 
beta in children with acute pyelonephritis and renal scarring. Nephrology 
Carlton, Vic. 2007;12(5):487–93.
30.  Fretzayas  A,  Moustaki  M,  Gourgiotis  D,  Bossios  A,  Koukoutsakis  P, 
Stavrinadis C. Polymorphonuclear elastase as a diagnostic marker of acute 
pyelonephritis in children. Pediatrics. 2000;105(2):E28.
31.  Arao S, Matsuura S, Nonomura M, Miki K, Kabasawa K, Nakanishi H. 
Measurement of urinary lactoferrin as a marker of urinary tract infection. 
Journal of Clinical Microbiology. 1999;37(3):553–7.
32.  Deo SS, Vaidya AK. Elevated levels of secretory immunoglobulin A (sIgA) 
in urinary tract infections. Indian Journal of Pediatrics. 2004;71(1):37–40.
33.  Bakakos  P,  Messaritaki A,  Mandyla  H,  Nicolaidou  P, Anagnostakis  D. 
Plasma and urine elastase alpha-1-proteinase inhibitor levels in neonatal 
urinary tract infection. Biology of the neonate. 2002;81(2):109–12.
34.  Everaert  K,  Oostra  C,  Delanghe  J,  Vande  Walle  J,  Van  Laere  M, 
Oosterlinck W. Diagnosis and localization of a complicated urinary tract 
infection in neurogenic bladder disease by tubular proteinuria and serum 
prostate specific antigen. Spinal Cord. 1998;36(1):33–8.
35.  Smith SD, Wheeler MA, Weiss RM. Detection of urinary tract infections by 
reduction of nitroblue tetrazolium. Kidney international. 1998;54(4):1331–6.
36.  Steinhoff J, Einecke G, Niederstadt C, et al. Renal graft rejection or urinary 
tract  infection?  The  value  of  myeloperoxidase,  C-reactive  protein,  and 
alpha2-macroglobulin in the urine. Transplantation. 1997;64(3):443–7.
37.  Kotoula A, Gardikis S, Tsalkidis A, et al. Procalcitonin for the early prediction 
of renal parenchymal involvement in children with UTI: preliminary results. 
International Urology and Nephrology. 2009;41(2):393–9.
38.  Leroy S, Romanello C, Galetto-Lacour A, et al. Procalcitonin to reduce the 
number of unnecessary cystographies in children with a urinary tract infection: 
a European validation study. The Journal of Pediatrics. 2007;150(1):89–95.
39.  Prat C, Dominguez J, Rodrigo C, et al. Elevated serum procalcitonin values 
correlate with renal scarring in children with urinary tract infection. The 
Pediatric Infectious Disease Journal. 2003;22(5):438–42.
40.  Tuerlinckx D, Vander Borght T, Glupczynski Y, et al. Is procalcitonin a good 
marker of renal lesion in febrile urinary tract infection? European Journal 
of Pediatrics. 2005;164(10):651–2.
41.  Roilides  E,  Papachristou  F,  Gioulekas  E,  et  al.  Increased  urine 
interleukin-6  concentrations  correlate  with  pyelonephritic  changes  on 
99mTc-dimercaptosuccinic  acid  scans  in  neonates  with  urinary  tract 
infections. The Journal of Infectious Diseases. 1999;180(3):904–7.
42.  Zaki  Mel  S.  Interleukin  8  is  a  surrogate  marker  for  rapid  diagnosis  of 
bacteriuria. Immunological Investigations. 2008;37(7):694–703.
43.  Oregioni O, Delaunay P, Bruna P, et al. Urinary interleukin-8 is elevated in urinary 
tract infections independently of the causative germs. Cytokine. 2005;31(6):415–8.
44.  Rao WH, Evans GS, Finn A. The significance of interleukin 8 in urine. 
Archives of Disease in childhood. 2001;85(3):256–62.
45.  Determann  RM,  Schultz  MJ,  Geerlings  SE.  Soluble  triggering  receptor 
expressed on myeloid cells-1 is not a sufficient biological marker for infection 
of the urinary tract. The Journal of Infection. 2007;54(6):e249–50.